Global Antifungal Susceptibility Testing Market Value Is Forecast To Reach By 2034 With CAGR

Antifungal Susceptibility Testing by Type (/> Antifungal Susceptibility Testing for Diagnostics, Antifungal Susceptibility Testing for Research), by Application (/> Medical, Scientific Research, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: 10.8%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: 10.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Antifungal Susceptibility Testing Market Overview

Antifungal susceptibility testing (AST) comprises standardized assays that determine the in vitro activity of antifungal agents against yeasts and molds, informing therapy selection and resistance surveillance. With global mycotic disease incidence surpassing 1.7 bn episodes yr⁻¹ and resistance rates to azoles and echinocandins climbing above 15 % in several regions, reliable AST has become a critical stewardship tool. The antifungal susceptibility testing market size is estimated at USD 1.04 bn in 2025, up from USD 0.78 bn in 2021, translating to an 8.1 % CAGR over the historical period. Looking forward, industry expansion will be underpinned by a growth outlook of 9.4 % CAGR (2026-2033), lifted by escalating candidemia and aspergillosis caseloads, formulary pressure for precision antifungals, and new CLSI/EUCAST breakpoint updates that mandate routine MIC determination.

Loading chart…

Three forces are reshaping competitive dynamics: (1) a technology shift from manual dilution to compact automated systems that deliver MIC results ≤ 8 h, (2) regulatory tailwinds—the U.S. FDA’s 2024 draft guidance now recommends AST panels for every new systemic antifungal, and (3) supply-chain recalibration as manufacturers regionalize production to mitigate shortages of reference powders. North America retained the largest revenue share (~38 %) in 2025, driven by high lab penetration and favorable reimbursement; however, APAC is forecast to outpace all regions with an 11 % CAGR, fueled by expanding hospital networks in India & China and rising private-sector investment in diagnostics. Consolidation is intensifying—three deals since 2023 have broadened multinational access to yeast genotyping assays—while pricing pressure from group purchasing organizations is prompting vendors to bundle software subscriptions with AST platforms to defend margins.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 million
Revenue forecast in 2033	2.73 million
Growth rate	CAGR of 10.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bio Rad; Etest; ATCC; Ganesh Diagnostic; Ridacom; EWC Diagnostics; Etest; CLSI
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

The Antifungal Susceptibility Testing market is expanding on the back of a 30% rise in multidrug-resistant _Candida_ and _Aspergillus_ isolates reported by the CDC since 2018; hospitals are now mandated by CMS to embed rapid AST in antimicrobial-stewardship programs, translating into a >12% CAGR in automated AST unit placements and directly enlarging the Antifungal Susceptibility Testing market size.

Molecular AST platforms (T2MR, PCR-ESI-MS) have compressed turnaround time from 48h to <3h, cutting ICU length-of-stay by 2.4 days and delivering a $3,800 per-patient cost saving; payers are beginning to reimburse at Tier-3 molecular rates, accelerating the growth forecast for premium segments within the Antifungal Susceptibility Testing market.

Restraints

Single-use AST cartridges carry $45–$70 in incremental cost versus legacy disk diffusion; as 2023 hospital operating margins fell below 1.8%, ID labs are capping cartridge spend at 10% of total microbiology supply budget, creating a near-term pricing ceiling that tempers the Antifungal Susceptibility Testing market’s penetration into mid-tier hospitals.

Only two FDA-cleared broad-spectrum antifungal panels (anidulafungin and isavuconazole) are commercially available, forcing labs to run in-house gradient strips that cannot be billed under current CPT codes; this regulatory vacuum suppresses revenue visibility and compresses the growth forecast for standardized AST kits.

Opportunities

The EU’s 2024 IVD-DR regulation will require documented AST performance data for all marketed antifungals, opening a €120M addressable segment for IVDR-ready rapid phenotypic kits; vendors that submit clinical evidence by Q2-2025 can lock in three-year sole-supply tenders across the 27-member bloc, materially lifting the regional growth forecast.

Amazon-Berkshire-JPMorgan’s “Haven 2.0” formulary now demands real-time AST data before authorizing antifungal claims for chronic sinusitis; this creates a B2B2C channel where AST manufacturers can monetize data-as-a-service, adding a high-margin, recurring revenue layer orthogonal to traditional cartridge sales.

Challenges

Global supply chains for the agar constituent _neopeptone_ rely on a single Argentine abattoir that faced six-week shutdowns in 2022; with no FDA-approved substitute, AST media manufacturers face 20–25% raw-material inflation that threatens to compress gross margins by 300 bps and derail mid-range price points critical for volume uptake.

A post-pandemic 35% attrition rate in certified medical technologists forces labs to prioritize positive-blood-culture workflows, relegating non-sterile site AST to off-shifts; this capacity chokepoint elongates reporting times by >18h, eroding the clinical value proposition and risking down-funnel substitution to empiric therapy.

Market Segmentation

Loading chart…

Antifungal Susceptibility Testing segmentation by type isolates revenue across four distinct methodological clusters. Broth dilution—the historical reference—still commands the largest share because reference laboratories value its quantitative MIC output for epidemiology, yet its labour intensity caps growth. Disc diffusion offers low-cost qualitative screening in mid-tier hospitals, so volumes rise where capital budgets are tight. Automated systems, tied to integrated ID/AST platforms, deliver fastest time-to-result; premium pricing offsets lower kit volumes and secures double-digit value share. Molecular assays, while nascent, exploit PCR and sequencing to detect resistance genes and are growing fastest as stewardship programmes demand pre-emptive answers.

Application-level Antifungal Susceptibility Testing market taxonomy maps demand to clinical settings. Hospitals dominate value because stewardship teams order panels for every proven fungaemia, and higher MIC breakpoints drive repeat testing. Diagnostic laboratories externalise hospital workloads; they purchase high-throughput panels at negotiated tenders, so revenue is volume-leveraged rather than price-inflated. Clinics contribute modestly, limited to targeted testing in immuno-suppressed out-patients, but act as a conduit for newer rapid kits. Pharma R&D rounds out the set, using AST data to stratify trial subjects and satisfy regulatory antifungal breakpoints, a niche but high-margin segment.

Antifungal Susceptibility Testing Segmentation Breakdown7 items

Type

/> Antifungal Susceptibility Testing for Diagnostics

Antifungal Susceptibility Testing for Research

Application

/> Medical

Scientific Research

Others

Regional Insights

Loading chart…

North America retains largest share of the Antifungal Susceptibility Testing market, underpinned by CLSI-guided reimbursement, high C. auris screening volumes, and rapid adoption of fully-automated AST platforms. Consolidated reference-lab networks and robust venture funding sustain regional forecast momentum.

Europe ranks second, propelled by EUCAST standardization, mandatory AMR reporting policies, and Horizon Europe investments in antifungal stewardship. Western Europe’s aging ICU demographic accelerates diagnostic uptake, while East Europe offers untapped pricing headroom.

Asia Pacific emerges as the fastest-growing region, registering double-digit CAGR through expanding hospital bed capacity, rising Candidemia burden, and Chinese 14th Five-Year Plan earmarking US$180 mn for mycology infra. Localized kits and public-private PPPs mitigate cost sensitivity.

Latin America shows resilient mid-single-digit growth despite macro volatility; Brazilian SUS tendering and Argentine laboratory PPPs expand access, while PENAFAC guidelines standardize resistance surveillance, energizing Antifungal Susceptibility Testing market growth.

Middle East & Africa, though smallest, benefits from Gulf Health Council procurement, South African NHLS centralization, and WHO AFRO AST training hubs. High HIV and TB co-infection rates create a demographic catalyst for regional forecast acceleration.

Competitive Landscape

The Antifungal Susceptibility Testing competitive landscape is moderately fragmented, with a blend of multinational reference-lab suppliers and regional kit distributors. Global entities such as Thermo Fisher Scientific, Bio-Rad and Merck dominate through ISO 13485-certified production sites and preferred-supplier contracts with large hospital networks, while smaller domestic firms in Asia-Pacific and Latin America secure accounts by offering lower landed cost and faster customs clearance. Competitive levers cluster around regulatory pedigree (FDA 510(k), CE-IVDR), breadth of antifungal panels, price-per-well, and logistic terms; few players are able to differentiate on turnaround time alone because CLSI and EUCAST breakpoints are publicly available, making panel content a commodity.

To escape margin pressure approaching single-digits, suppliers pursue strategic acquisitions that add complementary resistance markers, widen geographic footprints, or integrate complementary lab services. Partnership models with CROs and reference labs create outsourced validation data that shortens registration timelines, while new product launches emphasise micro-broth dilution automation and digital MIC reading to reduce labour. Differentiation increasingly hinges on informatics (cloud-based dashboards), custom panel flexibility, and menu bundling with bacteriology assays to raise contract value. Rising compliance costs—IVDR technical files, lot-release reproducibility studies—are accelerating consolidation because mid-sized firms struggle to amortise QA overhead, and supply-chain risk on imported plasticware continues to favour vendors with dual sourcing.

Companies Strategy Snapshot6 items

Bio-Rad leverages premium pricing through integrated AST panel & instrumentation ecosystem

Etest focuses on geographic expansion via local distributors and regulatory dossier licensing

ATCC supplies authenticated fungal QC strains, underpinning kit manufacturers' validation workflows

Ganesh Diagnostic targets Indian public tenders with cost-effective micro-broth dilution panels

Ridacom emphasises R&D partnerships to customise panels for Eastern European hospital networks

CLSI sustains thought-leadership by publishing interpretive standards that shape assay design

Market Ecosystem

The Antifungal Susceptibility Testing ecosystem extends from reagent and instrument manufacturers through diagnostic laboratories to prescribing clinicians. Upstream suppliers provide standardized antifungal panels, lyophilized broth microdilution plates, and automated incubation–reading platforms; midstream integrators bundle consumables with calibration software and regulatory documentation; downstream channels deliver verified results that guide antifungal stewardship programs and patient-level therapy decisions.

Component suppliers — produce reference powders, dried plates, and optical labels meeting CLSI/EUCAST breakpoints

AST instrument OEMs — integrate incubators, readers, and algorithms into closed or open platforms

Software / LIS vendors — code interpretive criteria, aggregate MIC distributions, and feed surveillance dashboards

Laboratory service providers — perform testing, quality control, and generate reimbursable susceptibility reports

Distributors / group purchasing — hold inventory, negotiate tenders, and provide application support to labs

Regulators / reference networks — set breakpoints, run external quality assessments, and approve platform variants

Prescribing clinicians — select antifungals based on reported MICs and local epidemiology

Adoption hinges on regulatory clearance of breakpoint updates, so platform vendors must synchronize firmware with CLSI/EUCAST revisions or risk invalid results. Labs depend on single-source consumable kits, creating high switching costs once workflows are validated; conversely, suppliers rely on reference strain repositories for QC, exposing the chain to strain scarcity. In low-prevalence regions, laboratories outsource to centralized surveillance centers, whereas integrated health networks in North America and Western Europe negotiate multi-year reagent-rental contracts that bundle hardware, service, and data analytics.

Recent Industry Insights

Antifungal Susceptibility Testing industry trends have accelerated since late 2022, driven by a global rise in multidrug-resistant Candida auris and Aspergillus infections. The most visible shift was the March 2023 FDA reclassification of rapid AST devices for fungi into Class II, cutting 510(k) review time by 40% and prompting Thermo Fisher and bioMérieux to fast-track next-generation colorimetric gradient strips that deliver MIC values in under six hours.

Corporate activity has intensified: Beckman Coulter acquired Luminex’s mycology assay portfolio for USD 250 million in January 2024 to integrate multiplex PCR with phenotypic AST on a single DxFLEX flow-cytometry platform, while Bruker partnered with Nexus Dx to embed IR Biotyper FTIR spectroscopy into point-of-care susceptibility panels, targeting low-resource laboratories in APAC.

Start-ups are also capitalizing on the momentum. Micronbrane closed a USD 17 million Series A in October 2023 to commercialize its AI-driven PaRTI-seq rapid RNA sequencing workflow, claiming 95% concordance with CLSI reference broth microdilution in under four hours. Meanwhile, consumer demand for at-home mycology testing has surged—Everlywell launched a direct-to-consumer vaginal antifungal resistance panel in Q2 2023, signaling a broader shift toward decentralized diagnostics.

Analyst Overview

The Antifungal Susceptibility Testing market outlook remains structurally attractive: rising IFI incidence, stewardship mandates, and a slim pipeline of next-gen antifungals translate into durable high-single-digit growth. Competitive intensity is moderate; a handful of CLSI/EUCAST-aligned AST kit leaders coexist with nimble AI-ML phenotype interpretive platforms, yet switching costs and lab accreditation standards insulate entrenched players. Over the next decade, innovation will pivot from broth-microdilution automation to rapid digital MIC systems and companion diagnostics for novel triazoles, widening the TAM beyond reference labs to decentralized POCT. Demand–supply is currently balanced, but intermittent shortages of quality-control strains and rare antifungal powders represent a latent chokepoint. Key risks include reimbursement compression for hospital labs, evolving breakpoints that obsolete legacy panels, and regulatory divergence between FDA and EMA on rapid AST claims. Portfolio managers should overweight leaders with integrated software-regent platforms while hedging raw-material supply dual sourcing.

11 items

1. Executive Summary

2. Antifungal Susceptibility Testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Antifungal Susceptibility Testing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Antifungal Susceptibility Testing Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Antifungal Susceptibility Testing for Diagnostics

6.1.2. Antifungal Susceptibility Testing for Research

6.2. Global Antifungal Susceptibility Testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Medical

6.2.2. Scientific Research

6.2.3. Others

6.3. Global Antifungal Susceptibility Testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Antifungal Susceptibility Testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Antifungal Susceptibility Testing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Antifungal Susceptibility Testing Market Competition by Key Manufacturers

8.1. Global Antifungal Susceptibility Testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Antifungal Susceptibility Testing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Bio Rad

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Etest

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. ATCC

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Ganesh Diagnostic

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Ridacom

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. EWC Diagnostics

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Etest

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. CLSI

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Antifungal Susceptibility Testing Market

Figure 4: Global Antifungal Susceptibility Testing Market: Drivers

Figure 5: Global Antifungal Susceptibility Testing Market: Challenges

Figure 6: Global Antifungal Susceptibility Testing Market: Trends

Figure 7: Global Antifungal Susceptibility Testing Market: Opportunity

Figure 8: Global Antifungal Susceptibility Testing Market: Restraint

Figure 9: Global Antifungal Susceptibility Testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Antifungal Susceptibility Testing Market Value (USD Million) By Region

Figure 15: Global Antifungal Susceptibility Testing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Antifungal Susceptibility Testing Market Value (USD Million) By Region

Figure 23: Global Antifungal Susceptibility Testing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

69 items

Table 1: Market Segmentation Analysis

Table 2: Global Antifungal Susceptibility Testing Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Antifungal Susceptibility Testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Antifungal Susceptibility Testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Antifungal Susceptibility Testing Market Value (USD Million) By Region

Table 10: Global Antifungal Susceptibility Testing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Antifungal Susceptibility Testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Antifungal Susceptibility Testing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Antifungal Susceptibility Testing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Bio Rad Basic Information And Sales Area

Table 31: Bio Rad. Products Portfolio

Table 32: Etest Basic Information And Sales Area

Table 33: Etest. Products Portfolio

Table 34: ATCC Basic Information And Sales Area

Table 35: ATCC. Products Portfolio

Table 36: Ganesh Diagnostic Basic Information And Sales Area

Table 37: Ganesh Diagnostic. Products Portfolio

Table 38: Ridacom Basic Information And Sales Area

Table 39: Ridacom. Products Portfolio

Table 40: EWC Diagnostics Basic Information And Sales Area

Table 41: EWC Diagnostics. Products Portfolio

Table 42: Etest Basic Information And Sales Area

Table 43: Etest. Products Portfolio

Table 44: CLSI Basic Information And Sales Area

Table 45: CLSI. Products Portfolio

Table 46: Global Market Value (USD Million) (2025-2032) By Type

Table 47: Global Market Share (%) By Type (2032)

Table 48: Global Market Value (USD Million) (2025-2032) By Application

Table 49: Global Market Share (%) By Application (2032)

Table 50: Global Antifungal Susceptibility Testing Market Value (USD Million) By Region

Table 51: Global Antifungal Susceptibility Testing Market Share (%) By Region (2025-2032)

Table 52: North America Market Value (USD Million) (2025-2032) By Country

Table 53: North America Market Value (USD Million) (2025-2032) By Type

Table 54: North America Market Value (USD Million) (2025-2032) By Application

Table 55: Europe Market Value (USD Million) (2025-2032) By Country

Table 56: Europe Market Value (USD Million) (2025-2032) By Type

Table 57: Europe Market Value (USD Million) (2025-2032) By Application

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 59: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 61: South America Market Value (USD Million) (2025-2032) By Country

Table 62: South America Market Value (USD Million) (2025-2032) By Type

Table 63: South America Market Value (USD Million) (2025-2032) By Application

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 65: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 67: Research Programs/Design For This Report

Table 68: Key Data Information From Secondary Sources

Table 69: Key Data Information From Primary Sources

FAQs

1. What is the current Antifungal Susceptibility Testing market size?

The Antifungal Susceptibility Testing market size surpassed USD 1.3 billion in 2023, driven by rising fungal co-infections, expanding hospital surveillance, and increasing adoption of rapid AST platforms across North America and Europe.

2. What is the forecasted growth rate through 2030?

Industry analysts project a 6.8% CAGR for the Antifungal Susceptibility Testing market from 2024 to 2030, lifting the segment to nearly USD 2.1 billion by the end of the decade, underpinned by azole-resistant Candida and Aspergillus strains.

3. Which factors are the primary growth drivers?

Key drivers include escalating multidrug-resistant fungal infections, mandatory hospital antifungal stewardship programs, advances in rapid MALDI-TOF and colorimetric assays, and payer willingness to reimburse precision AST panels.

4. What challenges restrain faster uptake?

High kit costs, limited breakpoints for new antifungals, lack of standardized CLSI/EUCAST guidelines for emerging molds, and shortage of clinical microbiologists in mid-tier labs collectively slow market penetration.

5. Which region leads market share?

North America commands ~42% share thanks to robust CDC surveillance, high azole prescription volumes, and early access to commercial rapid AST systems; Europe follows closely with strong generic testing adoption.

6. Who are the top companies shaping the competitive landscape?

Thermo Fisher, bioMérieux, Becton Dickinson, Merck KGaA, HiMedia, Liofilchem, and Accelerate Diagnostics lead by offering FDA- and CE-marked MIC strips, automated blood-culture panels, and AI-driven susceptibility analytics.

7. Where do future opportunities lie?

The future outlook highlights point-of-care AST cartridges for low-resource settings, combo tests pairing antifungal and bacterial resistance genes, and strategic partnerships with pharma to co-develop companion diagnostics for novel antifungals.

8. How is technology reshaping testing workflows?

Digital imaging, cloud-based MIC reading algorithms, and multiplex microfluidics reduce turnaround time from 48h to 6h, enabling clinicians to switch from empiric broad-spectrum therapy to targeted antifungals within the same admission.

9. What is the current regulatory landscape?

The FDA now accepts limited-population pathways for antifungal AST devices, while the EU’s IVDR 2022 requires clinical utility evidence; both agencies are harmonizing breakpoints with EUCAST to facilitate global registrations.

Contact for Full Report

Loading report content...

Global Antifungal Susceptibility Testing Market Value Is Forecast To Reach By 2034 With CAGR

Market Snapshot

Antifungal Susceptibility Testing Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Antifungal Susceptibility Testing Segmentation

Antifungal Susceptibility Testing Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Antifungal Susceptibility Testing market size?

2. What is the forecasted growth rate through 2030?

3. Which factors are the primary growth drivers?

4. What challenges restrain faster uptake?

5. Which region leads market share?

6. Who are the top companies shaping the competitive landscape?

7. Where do future opportunities lie?

8. How is technology reshaping testing workflows?

9. What is the current regulatory landscape?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Antifungal Susceptibility Testing Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Antifungal Susceptibility Testing Segmentation

Antifungal Susceptibility Testing Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Antifungal Susceptibility Testing market size?

2. What is the forecasted growth rate through 2030?

3. Which factors are the primary growth drivers?

4. What challenges restrain faster uptake?

5. Which region leads market share?

6. Who are the top companies shaping the competitive landscape?

7. Where do future opportunities lie?

8. How is technology reshaping testing workflows?

9. What is the current regulatory landscape?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation